Results 141 to 150 of about 3,808,290 (359)

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. [PDF]

, 2011
Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with leukaemia driven by BCR-ABL1 (ref. 1) and other oncogenic tyrosine kinases. Recent efforts have focused on developing more potent TKIs that also inhibit mutant tyrosine kinases ...
Braig, Melanie, Cerchietti, Leandro, Duy, Cihangir, Geng, Huimin, Graeber, Thomas G, Heisterkamp, Nora, Herzog, Sebastian, Hofmann, Wolf-Karsten, Hurtz, Christian, Jumaa, Hassan, Kim, Yong-mi, Klemm, Lars, Koeffler, H Phillip, Kweon, Soo-mi, Melnick, Ari, Müschen, Markus, Nahar, Rahul, Park, Eugene, Shojaee, Seyedmehdi, Swaminathan, Srividya, Wu, Hong, Ye, B Hilda, Yu, J Jessica   +22 more
core  

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Blood, 2016
D. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. Borowitz, M. L. Le Beau, C. Bloomfield, M. Cazzola, J. Vardiman   +8 more
semanticscholar   +1 more source

Macrophage Membrane‐Cloaked, ROS‐Triggered Quercetin Nanocarriers Target Ovarian Lesions to Treat Polycystic Ovary Syndrome

Advanced Healthcare Materials, EarlyView.
The synthesis process of MM@PCD@QNPs and its potential mechanism for treating PCOS. (A) Assembly steps of MM@PCD@QNPs. (B) Synthesis and decomposition of MM@PCD@QNPs. (C) Potential therapeutic mechanisms of MM@PCD@QNPs for PCOS. PCD, PABP conjugated with DEX polymer; QUR, quercetin; CDI, N, N′‐carbonyldiimidazole; DEX, dextran; PABP, 4‐(hydroxymethyl ...
Wenzhu Li, Yu Guan, Nan Song, Feng Zhang, Zhimin Deng, Tailang Yin, Yanbing Yang, João Conde, Wenyi Jin, Zhinang Yin   +9 more
wiley   +1 more source

Nanobody‐Conjugated Theranostic Prodrug Targeting αvβ3 Integrin Enables Precision Cancer Therapy With Real‐Time Imaging

Advanced Healthcare Materials, EarlyView.
The image shows a schematic form a nanobody‐conjugated theranostic prodrug (NBD) platform targeting tumor‐associated αvβ3 integrin. The NBD system integrates selective nanobody‐mediated tumor recognition, glutathione‐responsive disulfide cleavage for doxorubicin release, and aza‐BODIPY‐based near‐infrared fluorescence for real‐time imaging.
Sanu Karan, Hyunseung Lee, Rema Naskar, Mi Young Cho, Hye Sun Park, Eun Hee Han, Soumyadip Hore, Sun Hee Cho, Truc Ngoc Kim Lam, Taewoong Son, Tae Jung Park, Inkyu Hwang, Jonathan L. Sessler, Kwan Soo Hong   +13 more
wiley   +1 more source

Acute myeloid leukemia with fusion resembling acute promyelocytic leukemia, initially presenting as sweet syndrome: A case report and literature review

Journal of International Medical Research
Some subtypes of acute myeloid leukemia share morphologic, immunophenotypic, and clinical features of acute promyelocytic leukemia but lack a promyelocytic leukemia–retinoic acid receptor alpha fusion gene.
Huan Liu, Guo-Xia Liu, Feng-Hai Liu, Shu-Guo Wang   +3 more
doaj   +1 more source

A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

Frontiers in Oncology
Secondary acute lymphoblastic leukemia (s-ALL) refers to acute lymphoblastic leukemia that occurs after a previous malignant tumor, including therapy-related acute lymphoblastic leukemia (t-ALL) and prior malignant tumor acute lymphoblastic leukemia (pm ...
Mengci Hu, Wenzhe Li, Pan Li, Jie Tan, Ya Wang, Ya Wang   +5 more
doaj   +1 more source

Turning Unpredictable Biomolecule Adsorption to Controlled Corona Formation: Focus on Carbon Nanomaterials

Advanced Materials, EarlyView.
Controlling the protein corona formation onto carbon nanomaterials (CNMs) enhances their functionalities as platforms for cancer theranostics. Here, we reviewed the effects of the intrinsic and acquired properties of CNMs on protein corona formation, the consequent biological and toxicological outcomes, and the strategies to reshape corona formation ...
Yajuan Zou, Yalei Hu, Jie Yu, Naoki Komatsu, Yuta Nishina, Alberto Bianco   +5 more
wiley   +1 more source

A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. [PDF]

, 2011
Inhibition of farnesyltransferase (FT) activity has been associated with in vitro and in vivo anti-leukemia activity. We report the results of a phase 1 dose-escalation study of tipifarnib, an oral FT inhibitor, in patients with relapsed, refractory or ...
Forman, SJ, Frankel, P, Karanes, C, Kirschbaum, MH, Newman, EM, O'Donnell, MR, Popplewell, L, Pulone, B, Rincon, A, Stein, AS, Synold, T, Tuscano, J, Wright, J, Zain, JM   +13 more
core  

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Blood, 2009
J. Vardiman, J. Thiele, D. Arber, R. Brunning, M. Borowitz, A. Porwit, N. Harris, M. L. Le Beau, E. Hellström-Lindberg, A. Tefferi, C. Bloomfield   +10 more
semanticscholar   +1 more source

Microfluidic Hydroporation Platform for Effective Allogeneic CAR‐T Cell Production and Subsequent Functional Cytotoxicity Analysis

Advanced Materials Technologies, EarlyView.
The hydroporator platform employs controlled hydrodynamic deformation for efficient mRNA and CRISPR/Cas9 delivery into primary human T cells, enabling allogeneic CAR‐T cell manufacturing. It preserves cell functionality and drives potent gene editing, CAR expression, and tumor cytotoxicity, while feature‐based analysis links these functional outcomes ...
Soohyun Jeon, Sein Kim, Hyun‐Young Kim, Duck Cho, Sungsu Park, Seohyun Kim, Aram J. Chung   +6 more
wiley   +1 more source